StreetInsider.com News Articles

Odyssey Therapeutics to present OD-001 combo trial design at ACG 2026

Mon, 12 Oct 2026 08:00:14 -0400

Odyssey Therapeutics, Inc. (Nasdaq: ODTX) announced it will present the design of a Phase 2a clinical trial evaluating OD-001 in combination with vedolizumab for patients with moderate-to-severe ulcerative colitis at the American College of Gastroenterology 2026 Annual Scientific Meeting in Nashville, Tennessee, running October 9–14.

The randomized, double-blind, placebo-controlled trial is designed to enroll up to 146 patients globally. The study will evaluate OD-001 combined with vedolizumab during a 12-week induction period, followed by maintenance with OD-001 monotherapy through Week 52. The company expects to report topline induction results in the second half of 2027.

According to the company, OD-001 inhibits RIPK2-mediated

Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026

Mon, 12 Oct 2026 08:00:00 -0400

Topline induction results expected in the second half of 2027

BOSTON, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced that it will present the design of a randomized, double-blind Phase 2a trial evaluating OD-001 in combination with vedolizumab in patients with moderate-to-severe ulcerative colitis (UC) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting, taking place October 9-14,

Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026

Mon, 12 Oct 2026 08:00:00 -0400

Topline induction results expected in the second half of 2027

UBS Starts Odyssey Therapeutics (ODTX) at Buy

Mon, 12 Oct 2026 02:22:33 -0400

UBS analyst Alice Nettleton initiates coverage on Odyssey Therapeutics (NASDAQ: ODTX) with a Buy rating and a price target of $27.00.

The analyst comments: “We initiate coverage of Odyssey Therapeutics (ODTX) with a Buy rating and $27 PT. We view OD-001, a novel oral RIPK2 inhibitor, as a promising new therapy for inflammatory bowel disease (IBD), a market we estimate could reach $40-50B in 2035. In a single-arm Phase 2a study in ulcerative colitis (UC), OD-001 achieved a 27% clinical remission (CR), which we view as a respectable efficacy signal, with similar activity in advanced-therapy (AT) naïve and experienced patients and

UBS Starts Odyssey Therapeutics (ODTX) at Buy

Mon, 12 Oct 2026 02:22:33 -0400

UBS analyst Alice Nettleton initiates coverage on Odyssey Therapeutics (NASDAQ: ODTX) with a Buy rating and a price target of $27.00.

Raymond James Starts Odyssey Therapeutics (ODTX) at Outperform

Thu, 08 Oct 2026 16:06:53 -0400

(Updated - October 8, 2026 4:06 PM EDT)

Raymond James analyst Thomas Deal initiates coverage on Odyssey Therapeutics (NASDAQ: ODTX) with a Outperform rating and a price target of $42.00.

The analyst comments "We are initiating coverage of Odyssey Therapeutics (ODTX) with an Outperform rating and a $42 target price. Led by a team of experienced drug hunters, Odyssey is developing novel small molecule and protein therapeutics for high-value autoimmune and inflammatory conditions. Lead asset OD-001 is an oral RIPK2 scaffolding inhibitor in Phase 2 development for inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). We believe ODTX

Raymond James Starts Odyssey Therapeutics (ODTX) at Outperform

Thu, 08 Oct 2026 16:06:53 -0400

(Updated - October 8, 2026 4:06 PM EDT)

Raymond James analyst Thomas Deal initiates coverage on Odyssey Therapeutics (NASDAQ: ODTX) with a Outperform rating and a price target of $42.00.

Raymond James Starts Odyssey Therapeutics (ODTX) at Outperform

Thu, 08 Oct 2026 16:06:53 -0400

(Updated - October 8, 2026 4:06 PM EDT)

Raymond James analyst Thomas Deal initiates coverage on Odyssey Therapeutics (NASDAQ: ODTX) with a Outperform rating and a price target of $42.00.

Odyssey Therapeutics to present OD-001 ulcerative colitis data at UEG Week

Tue, 06 Oct 2026 08:00:11 -0400

Odyssey Therapeutics, Inc. (Nasdaq: ODTX) announced that additional Phase 2a induction data for its drug candidate OD-001 in moderate to severe ulcerative colitis will be presented at United European Gastroenterology (UEG) Week 2026 in Barcelona, Spain, on October 20.

The oral presentation, titled "Safety and Efficacy of OD-001, a First-in-class Oral RIPK2 Scaffolding Inhibitor, in Patients with Moderately to Severely Active Ulcerative Colitis: Results from a Phase 2a Trial," will be delivered by Bruce Sands, M.D., M.S., of the Icahn School of Medicine at Mount Sinai. The session is scheduled for 9:00 a.m. CEST and is listed as presentation number OP197.

Odyssey

Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026

Tue, 06 Oct 2026 08:00:00 -0400

Company to host conference call and webcast following the presentation on Tuesday, October 20, at 8:00 a.m. EDT

BOSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced that additional results from the OD-001 induction period of its Phase 2a trial in moderate to severe ulcerative colitis will be featured in an oral presentation at United European Gastroenterology

Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026

Tue, 06 Oct 2026 08:00:00 -0400

Company to host conference call and webcast following the presentation on Tuesday, October 20, at 8:00 a.m. EDT

Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum

Wed, 16 Sep 2026 08:00:00 -0400

BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced that members of its management team are scheduled to present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Wednesday, September 23 at 11:00 AM ET.

A live webcast will be available under “News and Events” in the Investors section of the Company’s website at

Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum

Wed, 16 Sep 2026 08:00:00 -0400

A live webcast will be available under “News and Events” in the Investors section of the Company’s website at

H.C. Wainwright Starts Odyssey Therapeutics (ODTX) at Buy

Thu, 27 Aug 2026 06:04:14 -0400

H.C. Wainwright analyst Emily Bodnar initiates coverage on Odyssey Therapeutics (NASDAQ: ODTX) with a Buy rating and a price target of $44.00.

The analyst comments "A clinical-stage I&I company built around a potential first-in-class oral RIPK2 scaffolding inhibitor. Odyssey Therapeutics is developing precision small molecules and protein therapeutics against upstream immune nodes where multiple inflammatory pathways converge. Lead asset OD-001 is an oral RIPK2 scaffolding inhibitor in Phase 2 development for ulcerative colitis (UC), with additional opportunity in Crohn's disease (CD). Rather than competing at the ATP site as prior kinase-directed programs did, OD-001 binds RIPK2 and blocks its recruitment of

H.C. Wainwright Starts Odyssey Therapeutics (ODTX) at Buy

Thu, 27 Aug 2026 06:04:14 -0400

H.C. Wainwright analyst Emily Bodnar initiates coverage on Odyssey Therapeutics (NASDAQ: ODTX) with a Buy rating and a price target of $44.00.

Odyssey Therapeutics to Participate in Upcoming Investor Conferences

Wed, 26 Aug 2026 08:00:00 -0400

BOSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced that members of its management team will participate in the following upcoming investor conferences in September:

2026 Cantor Global Healthcare Conference
Conference Dates: September 9-11, 2026
Location: New York, NY
Fireside Chat: September 9^th at 8:35AM ET
Morgan Stanley 24th Annual Global Healthcare Conference
Conference Dates: September

Odyssey Therapeutics to Participate in Upcoming Investor Conferences

Wed, 26 Aug 2026 08:00:00 -0400

2026 Cantor Global Healthcare Conference
Conference Dates: September 9-11, 2026
Location: New York, NY
Fireside Chat: September 9^th at 8:35AM ET
Morgan Stanley 24th Annual Global Healthcare Conference
Conference Dates: September

Odyssey Therapeutics (ODTX) PT Raised to $29 at JPMorgan

Fri, 07 Aug 2026 09:09:16 -0400

JPMorgan analyst Brian Cheng raised the price target on Odyssey Therapeutics (NASDAQ: ODTX) to $29.00 (from $26.00) while maintaining a Overweight rating.

Form 10-Q Odyssey Therapeutics, For: Jun 30

Thu, 06 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260806/26877483.html

Form 10-Q Odyssey Therapeutics, For: Jun 30

Thu, 06 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260806/26877483.html

Evotec and Odyssey partner on autoimmune drug discovery

Thu, 06 Aug 2026 06:00:24 -0400

Evotec SE (NASDAQ: EVO) and Odyssey Therapeutics, Inc. (NASDAQ: ODTX) have entered an R&D collaboration to discover small molecule drug candidates for autoimmune and inflammatory diseases, according to a press release from Evotec.

Under the agreement, Odyssey will use Evotec's discovery platform, screening capabilities, and AI-enabled data science tools to identify and validate drug candidates across multiple disease targets. The collaboration pairs Odyssey's disease biology expertise with Evotec's compound libraries and high-throughput experimentation capabilities.

Evotec is eligible to receive milestone payments tied to the delivery of validated hit series for each target. Detailed financial terms were not disclosed.

Evotec Chief Scientific Officer Dr.

Evotec and Odyssey partner on autoimmune drug discovery

Thu, 06 Aug 2026 06:00:24 -0400

Evotec is eligible to receive milestone payments tied to the delivery of validated hit series for each target. Detailed financial terms were not disclosed.

Evotec Chief Scientific Officer Dr.

Evotec and Odyssey partner on autoimmune drug discovery

Thu, 06 Aug 2026 06:00:24 -0400

Evotec is eligible to receive milestone payments tied to the delivery of validated hit series for each target. Detailed financial terms were not disclosed.

Evotec Chief Scientific Officer Dr.

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

Thu, 06 Aug 2026 02:16:00 -0400

Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs
Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need

HAMBURG, Germany, Aug. 6, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&D collaboration with Odyssey Therapeutics, Inc. (NASDAQ: ODTX) to discover potential new treatments in autoimmune and inflammatory diseases.

Under the agreement,

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

Thu, 06 Aug 2026 02:16:00 -0400

Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs
Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need

Under the agreement,